GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CalciMedica Inc (NAS:CALC) » Definitions » EV-to-FCF

CalciMedica (CalciMedica) EV-to-FCF : -0.80 (As of May. 15, 2024)


View and export this data going back to 2020. Start your Free Trial

What is CalciMedica EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, CalciMedica's Enterprise Value is $20.68 Mil. CalciMedica's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-25.73 Mil. Therefore, CalciMedica's EV-to-FCF for today is -0.80.

The historical rank and industry rank for CalciMedica's EV-to-FCF or its related term are showing as below:

CALC' s EV-to-FCF Range Over the Past 10 Years
Min: -1.01   Med: 0   Max: 1.4
Current: -0.8

During the past 6 years, the highest EV-to-FCF of CalciMedica was 1.40. The lowest was -1.01. And the median was 0.00.

CALC's EV-to-FCF is ranked worse than
100% of 378 companies
in the Biotechnology industry
Industry Median: 7.545 vs CALC: -0.80

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-15), CalciMedica's stock price is $5.48. CalciMedica's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-330.311. Therefore, CalciMedica's PE Ratio for today is At Loss.


CalciMedica EV-to-FCF Historical Data

The historical data trend for CalciMedica's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CalciMedica EV-to-FCF Chart

CalciMedica Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial - -15.53 0.77 -6.54 -0.20

CalciMedica Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.54 0.43 -0.15 -0.02 -0.20

Competitive Comparison of CalciMedica's EV-to-FCF

For the Biotechnology subindustry, CalciMedica's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CalciMedica's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CalciMedica's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where CalciMedica's EV-to-FCF falls into.



CalciMedica EV-to-FCF Calculation

CalciMedica's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=20.683/-25.73
=-0.80

CalciMedica's current Enterprise Value is $20.68 Mil.
CalciMedica's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-25.73 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CalciMedica  (NAS:CALC) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

CalciMedica's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=5.48/-330.311
=At Loss

CalciMedica's share price for today is $5.48.
CalciMedica's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-330.311.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


CalciMedica EV-to-FCF Related Terms

Thank you for viewing the detailed overview of CalciMedica's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


CalciMedica (CalciMedica) Business Description

Traded in Other Exchanges
N/A
Address
274 Redwood Shores Parkway, P.O. Box 144, Redwood City, CA, USA, 94065
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.
Executives
Robert N Wilson director C/O JOHNSON & JOHNSON, ONE JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
A. Rachel Leheny director, 10 percent owner, officer: Chief Executive Officer C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Eric W Roberts director, 10 percent owner, officer: Chief Business Officer VALENCE LIFE SCIENCES LLC, 500 PARK AVENUE 9TH FLOOR, NEW YORK NY 10022
Sudarshan Hebbar officer: Chief Medical Officer C/O CALCIMEDICA, INC., 505 COAST BOULEVARD SOUTH, LA JOLLA CA 92037
Fred A Middleton director, 10 percent owner 400 SOUTH EL CAMINO REAL STE 1200, SAN MATEO CA 94402-1708
Eric Bjerkholt director 132 PURDURE AVENUE, KENGSINGTON CA 94708
Sanderling Ventures Vii (canada), L.p. 10 percent owner 1300 S. EL CAMINO REAL, SUITE 203, SAN MATEO CA 94402
Sanderling Ventures Management Vi 10 percent owner 1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402
Sanderling Vi Beteiligungs Gmbh & Co Kg 10 percent owner 1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402
Sanderling Vi Limited Partnership 10 percent owner 1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402
Sanderling Venture Partners Vi Co Investment Fund Lp 10 percent owner 1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402
Sanderling Venture Partners Vi Lp 10 percent owner 1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402
Allan Shaw director C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018
Michael J. Dunn officer: President and COO C/O CALCIMEDICA, INC., 505 COAST BOULEVARD SOUTH, LA JOLLA CA 92037
Kenneth A. Stauderman officer: Chief Scientific Officer C/O CALCIMEDICA, INC., 505 COAST BOULEVARD SOUTH, LA JOLLA CA 92037